NeoGraph Analytics
BiotechnologyNorth America2023 – 2032

Global Microbiome Therapeutics Market Size, Share, Growth and Forecast to 2032

Global Microbiome Therapeutics market valued at USD 1.2B in 2023, projected to reach USD 8.6B by 2032 at 24.5% CAGR.

Revenue, 2023

$1.2B

Forecast, 2032

$8.6B

CAGR, 2024-2032

24.5%

Report Coverage

North America

Code: microbiome-therapeutics-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

The global microbiome therapeutics market, valued at USD 1.2 billion in 2023, is projected to reach USD 8.6 billion by 2032, growing at a 24.5% CAGR. Live biotherapeutic products (LBPs) dominate the innovation pipeline, led by Seres Therapeutics' FDA-approved SER-109. North America commands 42% market share, while Asia Pacific emerges as the fastest-growing region. Key growth drivers include the antibiotic resistance crisis, rising GI disorder prevalence, and expanding gut-brain axis research. Regulatory pathways are maturing, with FDA and EMA establishing frameworks for live biotherapeutic product approvals.

02

Key Highlights

1

Prescription LBPs like SER-109 lead clinical adoption, with multiple Phase III candidates advancing rapidly.

2

Antibiotic resistance crisis drives demand for microbiome-based alternatives to conventional therapies.

3

North America dominates with 42% share, but Asia Pacific grows fastest at 26.5% CAGR.

03

Market Overview

Market Context

The global microbiome therapeutics market is experiencing rapid expansion driven by rising antibiotic resistance, growing understanding of the gut-brain axis, and increasing prevalence of GI disorders. Live biotherapeutic products (LBPs) are emerging as the most promising segment, with Seres Therapeutics' SER-109 becoming the first FDA-approved treatment for recurrent C. difficile infection.

The global microbiome therapeutics market is expanding rapidly, driven by rising antibiotic resistance, growing GI disorder prevalence, and breakthrough LBP approvals. The market reached USD 1.2 billion in 2023 and is forecast to exceed USD 8.6 billion by 2032.

Market Stage

High growth

Adoption Level

Growing

Key Trends

FDA approval of SER-109 validates the LBP therapeutic category and accelerates pipeline developmentGut-brain axis research opens new therapeutic avenues in neurology and psychiatryDefined bacterial consortia replace crude FMT with standardized, reproducible therapiesPharma-biotech partnerships accelerate commercialization and manufacturing scale-upAI-driven microbiome biomarker discovery enhances patient stratification and trial design
04

Market Forecast & Data

Market Growth Forecast
2024-2032 · CAGR 24.5%

Base Year (2023)

$1.2B

Forecast (2032)

$8.6B

CAGR (2024-2032)

24.5%

Market size by year, 2024-2032, in USD Billion.
YearMarket size ($ Billion)
2023Base year$1.20B
2024$1.49B
2025$1.86B
2026$2.32B
2027$2.88B
2028$3.59B
2029$4.47B
2030$5.56B
2031$6.93B
2032$8.62B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Forecast Analysis

The market is projected to grow from USD 1.2B in 2023 to USD 8.6B by 2032, reflecting a 24.5% CAGR. Growth is fueled by expanding clinical trial pipelines, regulatory approvals, and rising investment from pharmaceutical giants. Oncology and neurology applications represent the fastest-growing therapeutic verticals.

Regional Market Analysis
Market share and growth rate by region
Regional market analysis — market share, growth rate and largest market by region.
RegionMarket shareGrowth rateLargest market
North America42.0%23.5%United States
Europe28.0%22.0%Germany
Asia Pacific30.0%26.5%China

North America

#1
Share: 42.0%CAGR: 23.5%

Largest market: United States

Europe

#2
Share: 28.0%CAGR: 22.0%

Largest market: Germany

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
05

Market Dynamics

  • Rising antibiotic resistance crisis demanding alternative therapeutic approaches
  • Increasing prevalence of gastrointestinal disorders including recurrent C. difficile infection
  • Expanding clinical evidence supporting microbiome-based interventions across multiple diseases
06

Market Segmentation

By Product Type
Market share distribution across 5 segments
By Product Type — market share by segment, in percent.
SegmentShare
Live Biotherapeutic Products (LBPs)FDA-regulated prescription microbiome drugs with the fastest pipeline growth.35.0%
ProbioticsEstablished consumer and clinical segment with broad OTC and prescription applications.30.0%
PrebioticsSubstrate-based products that selectively nourish beneficial gut microorganisms.18.0%
Fecal Microbiota Transplantation (FMT)Whole-microbiome approach primarily used for recurrent C. difficile infections.10.0%
SynbioticsCombined probiotic and prebiotic formulations for synergistic gut health benefits.7.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
By Therapeutic Area
Market share distribution across 6 segments
By Therapeutic Area — market share by segment, in percent.
SegmentShare
Gastrointestinal DisordersDominant segment driven by recurrent C. difficile, IBD, and IBS treatment demand.40.0%
OncologyMicrobiome modulation to enhance immunotherapy response and reduce toxicity.20.0%
Metabolic DisordersTargeting obesity, type 2 diabetes, and NAFLD through gut microbial pathways.15.0%
Neurological DisordersGut-brain axis interventions for autism, Parkinson's, and depression.12.0%
Infectious DiseasesPrevention and treatment of antibiotic-resistant infections via microbiome restoration.8.0%
OthersIncludes dermatological, immunological, and women's health applications.5.0%
Total100.0%
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.

By End User

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Retail Pharmacies
07

Regional Analysis

1

North America

Lead: United States
CAGR: 23.5%Share: 42.0%

Dominant region driven by FDA approvals, strong venture capital funding, and leading biotech companies.

2

Europe

Lead: Germany
CAGR: 22.0%Share: 28.0%

Second-largest market with strong regulatory frameworks and growing microbiome research infrastructure.

3

Asia Pacific

Lead: China
CAGR: 26.5%Share: 30.0%

Fastest-growing region fueled by rising healthcare expenditure, increasing GI disease burden, and expanding biotech sector.

Country-Level Analysis

Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. How these figures are produced.
Market share and growth rate by country
CountryShareGrowth
United States
38.0%
+23.0%
Germany
12.0%
+21.5%
China
10.0%
+28.0%
08

Competitive Landscape

S

Seres Therapeutics

United States

Leader150M

Market leader with FDA-approved SER-109 for recurrent C. difficile infection.

Leading microbiome therapeutics company and pioneer of FDA-approved live biotherapeutic products for recurrent C. difficile infection.

F

Finch Therapeutics

United States

Challenger85M

Rising challenger with CP101 showing 74.5% sustained cure rate in Phase III trials.

Innovative LBP developer with CP101 achieving 74.5% sustained cure rate in Phase III PRISM3 trial for recurrent CDI.

V

Vedanta Biosciences

United States

Follower

Pioneer in defined bacterial consortia targeting oncology and autoimmune indications.

Also profiled

F

Ferring B.V.

2.1B

Established Swiss-Dutch pharmaceutical company with a dedicated microbiome therapeutics division focused on reproductive health and GI disorders.

09

Recent Developments

25
2025Seres Therapeutics

SER-109 (Vowst) achieves full-year commercial launch with expanding payer coverage across major US health plans

25
2025Vedanta Biosciences

VE800 Phase II combination trial with checkpoint inhibitors in advanced melanoma reports positive interim data

24
2024Finch Therapeutics

CP101 demonstrates 74.5% sustained cure rate in Phase III PRISM3 trial for recurrent C. difficile infection

24
2024Ferring B.V.

Rebyota (RBX2660) receives FDA approval as first fecal microbiota-based therapeutic for recurrent CDI prevention

10

Regulatory Landscape

FDA has established a Live Biotherapeutic Product (LBP) regulatory framework under CBER with specific CMC and clinical guidance documentsEMA's Advanced Therapy Medicinal Product (ATMP) classification covers certain microbiome-based therapies requiring centralized authorization
11

Research Methodology

Primary research

  • Expert interviews with microbiome therapeutics researchers and clinical investigators
  • Surveys of gastroenterologists, oncologists, and infectious disease specialists
  • Interviews with regulatory consultants and payer analysts

Secondary research

  • Published industry reports from MarketsandMarkets, Grand View Research, and Mordor Intelligence
  • Company financial filings, investor presentations, and SEC disclosures
  • Peer-reviewed clinical trial data from PubMed and ClinicalTrials.gov
  • FDA and EMA regulatory databases and approval documents

Validation: Triangulation method combining primary expert insights with secondary financial and clinical data sources, cross-validated across multiple independent market estimates

12

Strategic Takeaways

Investors

High-growth pipeline stage presents entry opportunities, but regulatory uncertainty warrants portfolio diversification across therapeutic areas.

Operators

Early partnerships with biotech innovators and investment in GMP manufacturing infrastructure are critical competitive differentiators.

13

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.